01.4
Capital Market and Stock
INVESTOR RELATIONS
Comprehensive, transparent and timely information about the capital markets remained at the center of our investor relations activities in 2008. We provide market participants with extensive information to enable them to make a fair assessment of the Company’s situation.
We issue detailed quarterly and annual reports with comprehensive segment reporting and extensive notes. We publish our reports promptly and fulfil the requirements of the various guidelines we are held to observe in both the U.S. and Germany. These include the German Corporate Governance Code, the Sarbanes-Oxley Act, and the regulations of Deutsche Börse and the New York Stock Exchange. More information on corporate governance can be found here.
We broadcast analyst conferences on the publication of our quarterly reports live on the Internet and offer web casts of these meetings for replay online. Our shareholders can also watch the speech given by the Chairman of the Management Board at the Annual General Meeting live on our website.
In 2008, we further intensified our contact with financial analysts as well as with institutional and private investors worldwide. We introduced Fresenius Medical Care in a total of 1,176 one-on-ones with analysts and investors - 34 % more than in 2007 – and answered questions about our business development and the Company’s future. In addition, we presented the Company and its perspectives at 24 roadshows and 28 investment conferences around the globe. Private investors also play an important role. For this reason, we were present several times at events staged by Germany’s leading association of private investors, the Deutsche Schutzvereinigung für Wertpapierbesitz (DSW).
2008 was also a highly successful year for the Investor Relations department. Our company received several awards for its investor relations work. The magazine “Capital” and the Society of Investment Professionals in Germany (Deutsche Vereinigung für Finanzanalyse und Asset Management, DVFA) awarded Fresenius Medical Care for the best IR work of all the companies in the DAX 30 index. The U.S. magazine “Institutional Investor” ranked our company number one in the “healthcare” category in Europe. Our annual report 2007 won second place in the DAX 30 in a competition held by “managermagazin” and received several awards from the U.S. League of American Communications Professionals (LACP). Furthermore, our company was presented with the Thomson Extel Pan-European IR Excellence Award in the Medtech & Services category for its outstanding investor relations work.
If you would like to contact Fresenius Medical Care Investor Relations or find out about key dates in our financial calendar 2009, please take a look here – or visit us at www.fmc-ag.de.
| Table 01.4.7 | KEY FIGURES OF FRESENIUS MEDICAL CARE SHARES |
| 2008 | 2007 | ||||||
|---|---|---|---|---|---|---|---|
| Ordinary share |
Preference share |
Ordinary share |
Preference share |
||||
| Authorized capital | $ in thousands | 363,076 |
4,240 |
361,384 |
4,191 |
||
| Number of shares | millions | 293.93 |
3.81 |
292.79 |
3.78 |
||
| Closing prices (Xetra trading) | |||||||
| High | € | 39.10 |
37.60 |
38.67 |
36.78 |
||
| Low | € | 29.73 |
28.31 |
33.05 |
31.32 |
||
| Year-end | € | 33.31 |
33.50 |
36.69 |
35.39 |
||
| Average daily trading volume | Shares | 1,498,696 |
1,698 |
1,691,393 |
4,421 |
||
| Closing price (ADS – NYSE) | |||||||
| High | $ | 59.01 |
55.00 |
56.70 |
53.50 | ||
| Low | $ | 39.84 |
31.00 |
43.69 |
40.00 |
||
| Year-end | $ | 47.18 |
43.00 |
52.75 |
51.34 |
||
| Market capitalization | |||||||
| Year-end | € in billions | 9.79 |
0.13 |
10.74 |
0.13 |
||
| Total | € in billions | 9.92 |
10.87 |
||||
| Index weight | |||||||
| DAX | % | 1.41 |
– |
0.86 |
– |
||
| Dividend | |||||||
| Per share 1 | € | 0.58 |
0.60 |
0.54 |
0.56 |
||
| Dividend yield | % | 1.7 |
1.8 |
1.5 |
1.6 |
||
| Distribution amount | € in millions | 173 |
160 |
||||
| Earnings per share (EPS) | |||||||
| Number of shares 2 | millions | 293.23 |
3.80 |
291.93 |
3.74 |
||
| Earnings per share (EPS) | $ | 2.75 |
2.78 |
2.43 |
2.45 |
||
| 1 2008: Proposal for approval at the Annual General Meeting on May 7, 2009. 2 Weighted average of outstanding shares. For a more detailed version, please refer to the 5-Year Summary. |
|||||||
